Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Janakiraman Subramanian"'
Autor:
Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L. Bajor, Patricia Cruz, J. Thaddeus Beck, Srimoyee Ghosh, Christine Dabrowski, Grace Antony, Tao Duan, Jennifer Veneris, Eleftherios Zografos, Janakiraman Subramanian
Publikováno v:
Clinical lung cancer. 23(7)
Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort exp
Publikováno v:
Clinical Lung Cancer. 18:e315-e325
Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to re
Autor:
Jonathan K. Kish, Agnieszka Cseh, Barbara Moehring, Wenbo Tang, Elizabeth Terlizzi, Edward S. Kim, Janakiraman Subramanian
Publikováno v:
Clinical Lung Cancer. 22:292-300.e1
Background The ErbB family blocker, afatinib, is approved for patients with squamous cell carcinoma (SqCC) of the lung following platinum-doublet chemotherapy but has not been explored following immunochemotherapy. Here, we assessed the characteristi
Autor:
Feng Gao, Leonardo Faoro, Janakiraman Subramanian, Everett E. Vokes, Ramaswamy Govindan, Ezra E.W. Cohen, Mark Kozloff, Ravi Salgia, Livia Szeto, Theodore Karrison
Publikováno v:
Clinical Lung Cancer. 13:123-128
Background This trial focused on optimally combining existing targeted therapies and cytotoxic chemotherapy in the treatment of unselected patients with advanced non–small-cell lung cancer (NSCLC). Methods Patients with previously untreated advance
Publikováno v:
Clinical Lung Cancer. 12:94-99
A number of novel agents are currently being tested in clinical trials in patients with cancer. Results from early-phase trials, often in unselected groups of patients with a wide variety of cancer types, were reported at the 46th annual meeting of t
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Publikováno v:
Clinical Lung Cancer. 11:311-319
Angiogenesis is essential for cancer growth and progression. Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis. The addition of bevacizumab, an antibody to vascular endothelial growth factor (VEGF), to paclitaxel and carb
Publikováno v:
Clinical lung cancer. 9(5)
Small-cell lung cancer (SCLC) accounts for 13% of all lung cancer cases in the United States.1 A majority of the patients present with advanced disease. Despite impressive initial responses, death from relapsed disease is almost inevitable in extensi